Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer

Phase 2/3 Completed 53 enrolled M.D. Anderson Cancer Center Helsinn Healthcare SA · collab National Cancer Institute (NCI) · collab

RandomizedParallel-groupDouble-blindSupportive care

Summary

This randomized phase II/III trial studies how well netupitant and palonosetron hydrochloride works in preventing chronic nausea and vomiting in patients with cancer. Netupitant and palonosetron hydrochloride may reduce nausea and vomiting.

Timeline

Start: 2017-05-03
Primary completion: 2022-02-14
Completion: 2022-02-14

Publications

Hui D, Puac V, Shelal Z, Liu D, Maddi R, Kaseb A, Javle M, Overman M, Yennurajalingam S, Gallagher C, Bruera E. Fixed-Dose Netupitant and Palonosetron for Chronic Nausea in Cancer Patients: A Double-Blind, Placebo Run-in Pilot Randomized Clinical Trial. J Pain Symptom Manage. 2021 Aug;62(2):223-232.e1. doi: 10.1016/j.jpainsymman.2020.12.023. Epub 2021 Jan 1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Netupitant	Small molecule	—	Oral
Subject	Palonosetron	Other / unclassified	—	Oral

Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer

Summary

Timeline

Publications

Drugs

Indications